NXGL vs. APYX, SEPA, CTCX, NUVO, DRIO, LNSR, ICCM, CTSO, LUCD, and DXR
Should you be buying NEXGEL stock or one of its competitors? The main competitors of NEXGEL include Apyx Medical (APYX), SEP Acquisition (SEPA), Carmell (CTCX), Holdco Nuvo Group D.G (NUVO), DarioHealth (DRIO), LENSAR (LNSR), IceCure Medical (ICCM), Cytosorbents (CTSO), Lucid Diagnostics (LUCD), and Daxor (DXR). These companies are all part of the "surgical & medical instruments" industry.
NEXGEL (NASDAQ:NXGL) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
2.2% of NEXGEL shares are held by institutional investors. Comparatively, 55.3% of Apyx Medical shares are held by institutional investors. 27.2% of NEXGEL shares are held by company insiders. Comparatively, 13.1% of Apyx Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
NEXGEL has higher earnings, but lower revenue than Apyx Medical. NEXGEL is trading at a lower price-to-earnings ratio than Apyx Medical, indicating that it is currently the more affordable of the two stocks.
Apyx Medical has a consensus price target of $6.17, suggesting a potential upside of 273.74%. Given Apyx Medical's higher possible upside, analysts clearly believe Apyx Medical is more favorable than NEXGEL.
In the previous week, Apyx Medical had 1 more articles in the media than NEXGEL. MarketBeat recorded 4 mentions for Apyx Medical and 3 mentions for NEXGEL. Apyx Medical's average media sentiment score of 1.33 beat NEXGEL's score of 0.51 indicating that Apyx Medical is being referred to more favorably in the news media.
Apyx Medical received 76 more outperform votes than NEXGEL when rated by MarketBeat users. Likewise, 61.60% of users gave Apyx Medical an outperform vote while only 50.00% of users gave NEXGEL an outperform vote.
Apyx Medical has a net margin of -45.20% compared to NEXGEL's net margin of -67.48%. NEXGEL's return on equity of -54.71% beat Apyx Medical's return on equity.
NEXGEL has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
Summary
Apyx Medical beats NEXGEL on 11 of the 17 factors compared between the two stocks.
Get NEXGEL News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NXGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
